Australia's most trusted
source of pharma news
Wednesday, 02 July 2025
Posted 31 January 2024 PM
In a surprise move Eli Lilly has halted the launch of Omvoh and called for "substantial policy change" in Australia after struggling to secure a feasible price for the first-in-class ulcerative colitis (UC) treatment.
It only took the company one attempt to secure the PBAC's recommendation for the anticipated blockbuster as a treatment for moderate to severe UC at the committee's July 2023 meeting.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.